Home / About Us / Meet Our Directors

Meet Our Directors

Keith Widdowson

Chairman

Keith has lived and managed regional pharmaceutical businesses in South Africa, Australia and also Asia Pacific from Singapore. Prior to that, he managed global pharmaceutical exports for Fisons from the UK. More recently, he has worked for 3i providing industry expertise for life science investments in Europe. Keith is now involved in pharmaceutical business consultancy and funding, as well as business mentoring.

Yvonne Barnett

Yvonne has a BSc (Hons) in Biomedical Science and a PhD in Biochemistry and Genetics, she is Senior Pro Vice-Chancellor (Research) at Nottingham Trent University. She has active research interests in causes and mechanisms of cancer and ageing and has authored in excess of 100 peer-reviewed original research papers, attracted several million pounds of funding support for research from a range of funding agencies and has long-standing collaborations with Centres of Excellence worldwide.  Yvonne was founding Director of the University Alliance Doctoral Training Alliance in Applied Biosciences for Health, which is the topic of her address to the 2017 HUCBMS conference.

Faz Chowdhury

Faz is CEO of Nemaura Pharma Limited. He originally trained as a pharmaceutical scientist, and subsequently completed a Masters in Microsystems and Nanotechnology at Cranfield University , and undertook Doctoral Research at the University of Oxford on nano-drug delivery. His experience in the Pharma Industry spans product development, manufacturing, technical and corporate management. He has numerous patents in the field of drug delivery devices and formulations.

Peter Rose

Peter is the UK’s Managing Director of Maetrics Ltd., formerly High Edge Consulting, which he founded in 2002, to assist medical device manufacturers with their worldwide quality systems, regulatory affairs and microbiological audits & reviews. He is a lead auditor and a degree qualified microbiologist.
Having worked in the medical device industry for 20 years, Peter has a wealth of experience and knowledge in quality and regulatory affairs in the medical devices sector.

Dave Mead

Dave, Managing Director of Mead BioAssociates Ltd., has more than twenty years’ experience in the development and commercialisation of biopharmaceutical processes, technologies and products. He received his PhD in biotechnology from the University of Manchester. Dave has previously worked at GSK, Novozymes, Albumedix and Delta Biotechnology and held a number of senior management positions in R&D, manufacturing and IP. Mead BioAssociates provide comprehensive business development, licensing, IP and management expertise to commercialise innovation in the Life Sciences from drug development & bioprocess technologies to MedTech.

Dr Nik Kotecha

As Chief Executive Officer at Morningside Pharmaceuticals Ltd, Nik has utilised his passion for drug discovery, International Trade and providing quality, affordable healthcare to forge a highly successful career. Nik started his education at Newcastle; then he went on to do a PhD at Imperial College in London, towards the identification of Novel Molecules in Drug Discovery; finally further Doctorate work at Cambridge University. Nik has previously worked with GSK (formerly SB) and Roche Pharmaceuticals. Having worked in the development, manufacture and supply of pharmaceutical products for 25 years, Nik has a wealth of experience in quality and regulatory affairs. Nik is also the Chair of the International Trade Steering Group for the East Midlands Chamber of Commerce.

Professor Mike Hannay

Mike is Managing Director at the East Midlands Academic Health Science Network (EMAHSN) and Chair of the AHSN Network, he has more than 25 years’ experience of working in the pharmaceutical industry, with an excellent track record of building collaboration with healthcare and academia.
He joined EMAHSN in July 2016 from ThermoFisher Scientific, where he had worked since 2013 as Vice President for the UK BioPharma Services Division.
That role built upon his significant experience both nationally and internationally, including Vice President of Medicines Development at AstraZeneca.  In his role with EMAHSN, Mike leads the organisation in helping to address some of the biggest health challenges facing the region.  Mike is currently Chair of the National AHSN Network, a collaboration of England’s 15 AHSNs.